RhumbLine Advisers
ZNTL icon

RhumbLine Advisers’s Zentalis Pharmaceuticals ZNTL Stock Holding History

RhumbLine Advisers’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-84,542
Closed -$134K – 4276
2025
Q1 		$134K Sell
84,542
-7,672
-8% -$16.5K ﹤0.01% 3289
2024
Q4 		$279K Buy
92,214
+5,501
+6% +$18K ﹤0.01% 3032
2024
Q3 		$319K Sell
86,713
-7,500
-8% -$27.3K ﹤0.01% 2989
2024
Q2 		$385K Buy
94,213
+11,451
+14% +$128K ﹤0.01% 2845
2024
Q1 		$1.3M Buy
82,762
+1,962
+2% +$27K ﹤0.01% 2109
2023
Q4 		$1.22M Sell
80,800
-70
-0.1% -$1.02K ﹤0.01% 2149
2023
Q3 		$1.62M Buy
80,870
+14,070
+21% +$357K ﹤0.01% 1962
2023
Q2 		$1.88M Buy
66,800
+2,093
+3% +$50.2K ﹤0.01% 1939
2023
Q1 		$1.11M Buy
64,707
+6,730
+12% +$136K ﹤0.01% 2072
2022
Q4 		$1.17M Buy
57,977
+3,120
+6% +$67.1K ﹤0.01% 2048
2022
Q3 		$1.19M Buy
54,857
+9,173
+20% +$251K ﹤0.01% 2047
2022
Q2 		$1.28M Buy
45,684
+7,761
+20% +$206K ﹤0.01% 2016
2022
Q1 		$1.75M Buy
37,923
+2,475
+7% +$134K ﹤0.01% 1885
2021
Q4 		$2.98M Buy
35,448
+782
+2% +$60.5K ﹤0.01% 1666
2021
Q3 		$2.31M Buy
34,666
+2,776
+9% +$160K ﹤0.01% 1825
2021
Q2 		$1.7M Buy
31,890
+1,281
+4% +$68.6K ﹤0.01% 2021
2021
Q1 		$1.33M Sell
30,609
-1,848
-6% -$79.6K ﹤0.01% 2079
2020
Q4 		$1.69M Buy
32,457
+20,347
+168% +$918K ﹤0.01% 1926
2020
Q3 		$396K Sell
12,110
-1,031
-8% -$36.1K ﹤0.01% 2396
2020
Q2 		$631K Buy
+13,141
New +$504K ﹤0.01% 2242

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

RhumbLine Advisers's ZNTL Position: Q2 2025 in Review

RhumbLine Advisers sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 84,542 shares — an estimated $134K sold.

RhumbLine Advisers first reported a position in ZNTL in Q2 2020 and held it in 20 quarters. The position peaked at $2.98M in Q4 2021. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • RhumbLine Advisers reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 84,542 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $134K.
  • RhumbLine Advisers first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 20 quarters.
  • RhumbLine Advisers's Zentalis Pharmaceuticals position peaked at $2.98M in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.